Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Chasing amylin: Must-have obesity target key to Roche-Zealand deal

Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target

March 12, 2025 9:51 PM UTC

The temperature just went up a few more degrees for obesity’s hottest target now that Roche is spending nearly $1.7 billion up front to license half of the U.S. and European rights to Zealand Pharma’s amylin agonist petrelintide. The financials are big, but the most important consideration for the Danish biotech in the hyper-competitive bidding process was gaining a partner committed to investing in the opportunity — including manufacturing — to make the obesity programs a commercial success.

Amylin has quickly become a must-have target for any pharma with long-term ambitions to compete with obesity leaders Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) and Eli Lilly and Co. (NYSE:LLY). Roche (SIX:ROG; OTCQX:RHHBY) signaled as much today in its deal with Zealand Pharma A/S (CSE:ZEAL), through which the Swiss pharma gained rights to amylin agonist petrelintide...

BCIQ Company Profiles

Roche

Zealand Pharma A/S

BCIQ Target Profiles

Amylin receptor